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BACKGROUND
Asthma is characterised by variable symptoms of wheeze,
shortness of breath, chest tightness and/or cough, and by variable
expiratory ﬂow limitation.1 Asthma can affect patients at any age
with varying severities. Until recently, asthma has been considered
to be a single, allergic, eosinophilic, TH2-mediated and
glucocorticoid-responsive disease.2,3 Recently, cluster analyses
have suggested that patients with asthma can be divided into
different phenotypes, and the age at disease onset was found as a
key differentiating factor between phenotypes.2,3 Later- or adult-
onset disease is less associated with allergy than asthma
beginning in childhood. Adult-onset phenotypes such as late-
onset eosinophilic (often severe), exercise-induced, obesity-related
and neutrophilic asthma have been proposed.2,3 Most publica-
tions on asthma have focused on allergic asthma starting in
childhood.2,3 The symptoms in childhood are often transient, and
approximately three out of four asthmatic children will outgrow
their asthma.4 In contrast, the long-term prognosis of adult-onset
asthma is not known, and only two5,6 follow-up studies of
duration of 2–5.8 years have been published and suggest a less
favourable outcome. Thus, long-term, real-life, follow-up studies
with asthma patients treated in primary care are needed.
Allergic childhood asthma can usually be treated well by inhaled
glucocorticoids,2–4 whereas the need for different add-on
therapies7 is common in adult-onset disease and the therapeutic
response may remain insufﬁcient.2,3,7 In adult patients with
asthma, co-morbidities are common.8,9 Still, a single-disease
paradigm dominates randomised controlled trials, health policy,
delivery and guidelines.8 The current guidelines on diagnostics
and treatment of asthma1,10 or asthma–chronic obstructive
pulmonary disease (COPD) overlap syndrome1,11,12 offer us advice
and information mainly on the epidemiology, risk factors,
diagnostic criteria, (initial) pharmacotherapy and treatment of
exacerbations. However, when it comes to exact recommenda-
tions on whether the diagnostic studies and the diagnosis of
asthma should be made in primary practice, the recommenda-
tions, if they exist at all, are based on opinion rather than on
evidence. Furthermore, a similar lack of information remains when
speciﬁc questions on the organisation of the follow-up of
chronically ill patients with asthma are asked. Examples of such
questions are as follows: who should perform the follow-up
checks? How often should these follow-up checks be performed?
Exactly what follow-up tools should be used?
AIMS
The aim of this study is to increase the understanding on the
diagnostics and diagnostic process, organisation of the long-term
asthma care, therapeutic outcomes, prognosis and the factors
affecting the prognosis of new-onset asthma diagnosed at
adult age.
METHODS
Study design, inclusion and exclusion criteria
Seinäjoki Adult Asthma Study (SAAS) is a single-centre (Department of
Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland) 12-year
follow-up study of a total cohort of 259 patients having new-onset asthma
that was diagnosed at adult age. However, two patients were excluded
because they were later found to have a previous diagnosis of asthma
during childhood, leaving 257 patients in the original cohort. The study
was divided in two parts (Figure 1): the collection of the original cohort
(phase I) and follow-up visit (phase II). The original cohort was collected
between 6 October 1999 and 17 April 2002. Patients were referred to the
hospital by primary-care practitioners because of suspicion of asthma.
Inclusion and exclusion criteria are shown in Table 1. Patients with
simultaneous asthma and COPD were not excluded, and the study
population includes patients who could be deﬁned as having asthma–
COPD overlap syndrome, even though the inclusion criteria for those
patients are not exactly the same as currently used criteria for asthma–
COPD overlap syndrome.1,11,12
After 12 years, patients were invited to a follow-up visit (phase II;
10 December 2012 and 31 October 2013) in which asthma status,
co-morbidities (chronic rhinitis or obstructed nose, allergic rhinitis or
conjunctivitis, diabetes, hypertension, coronary heart disease, COPD and
any other patient-reported disease), medication (including medication to
other diseases and the disease treated), control, severity and lung function
were evaluated (Figure 1). In addition to the data gathered at these visits,
data on asthma follow-up visits, exacerbations, hospitalisations, possible
occupationally induced asthma and prescribed asthma medication were
collected from hospital clinics, primary health care, occupational health
care and private practices for the whole 12-year follow-up period. In
addition, the use of medication that was realised, i.e., medication bought
from pharmacy, will be retrieved. In addition to asthma-speciﬁc factors,
data include occupational, lifestyle and socioeconomic factors at the
follow-up visit.
Ethical considerations and permissions
Phase I was originally designed as a registry serving as an asthma-related
data exchange platform between primary and specialised care, as well as
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an asthma-related research registry. Phase I was part of hospital
development projects (institutional permission TU 1114). No interventions
outside normal clinical practice were carried out. All participants in the
original cohort gave written informed consent to be included in the
registry. With the development of a common regional electronic patient
record system, the data exchange platform became unnecessary, but the
research registry remained. The participants of the follow-up visit (phase II)
gave written informed consent to the study protocol approved by the
Ethics committee of Tampere University Hospital, Tampere, Finland
(R12122).
Setting and background data
The organisation of asthma care in general and especially in the Seinäjoki
Central Hospital district has recently been described in detail.13 Asthma is a
common disease needing community solutions.14 The actions of the
Finnish Asthma Programme14,15 have been put into practice in the hospital
district.13,16 The original cohort (phase I) represents novel adult asthma
cases well; for example, the total number of new diagnoses of asthma at
the study centre in 2001 was 133.16 Of those, 126 patients were recruited
to phase I of this study, representing 94.7% of new diagnoses of asthma.
The main planned outcomes
Prognosis of new-onset asthma diagnosed at adult age during a
12-year follow-up. The questions the clinician is facing in front of an
adult patient with newly diagnosed asthma are as follows: what is the
prognosis of adult-onset asthma in general and especially in this particular
patient? Are there any prognostic markers that would help me in
predicting the future and guide me in planning his/her future therapy?
The primary outcome is the prognosis of asthma (remission, control and
severity). However, evaluation of control at a single time point does not
represent the true morbidity of asthma.17 Our intention is to characterise
the true 12-year prognosis of asthma, i.e., cumulative burden of asthma-
related events, which is the second primary outcome. Secondary outcomes
include the following: exacerbations, hospitalisations and mortality
because of asthma, multimorbidity, lung function and inﬂammatory cells
(e.g., blood eosinophils and neutrophils), as well as inﬂammatory and other
markers of interest18–21 in the pathogenesis of asthma such as interleukins,
adipokines and periostin (Figure 1).
Diagnostics and follow-up of patients with adult-onset asthma in
primary and specialised care. The diagnosis of asthma with all patients
Figure 1. Schematic presentation of the Seinäjoki Adult Asthma Study. The original cohort (phase I) was collected between 6 October 1999
and 17 April 2002, and follow-up visit (phase II) was performed between 10 December 2012 and 31 October 2013.
Table 1. Inclusion and exclusion criteria used in SAAS
Inclusion
criteria
● A diagnosis of new-onset asthma made by a respiratory specialist
● Diagnosis conﬁrmed by at least one of the following objective lung function measurements:a
J FEV1 reversibility in spirometry of at least 15% and 200ml
J Diurnal variability (⩾20%) or repeated reversibility (⩾15%/60 l/min) in PEF follow-up
J A signiﬁcant decrease in FEV1 (15%) or PEF (20%) in response to exercise or allergen
J A signiﬁcant reversibility in FEV1 (at least 15% and 200ml) or signiﬁcant mean PEF change in response to a trial with oral or
inhaled glucocorticoids
● Symptoms of asthma
● Age ⩾ 15 years
Exclusion
criteria
● Physical or mental inability to provide signed informed consent
● Diagnosis of asthma below the age of 15 years
● Of note:
J Patients with comorbidities, either other lung disease or any other signiﬁcant disease, were not excluded
J Patients were not excluded because of smoking, alcohol use or any other lifestyle factor
J Respiratory symptoms or any other disease during childhood was not a reason to exclude patients, but a diagnosis of asthma at
age o15 years was an exclusion criteria
Abbreviations: FEV1, forced expiratory volume in one second; PEF, peak expiratory ﬂow; SAAS, Seinäjoki Adult Asthma Study.
aThe objective lung function criteria reﬂect those of National and International Guidelines valid in 1999–2002 and may not exactly follow those valid at the
moment.1,10
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in the present study was conﬁrmed by a respiratory specialist, but
diagnostic studies for most patients were partly performed already in
primary care. This gives us the opportunity to assess the proportion of
diagnoses that could have been done already in primary care and the
diagnostic tools that were able to provide sufﬁcient information on the
diagnosis of adult-onset asthma in primary care. All asthma-related follow-
up visits over a 12-year period both in primary and specialised care are
collected and evaluated. Thus, the impact of asthma follow-up visits on the
outcome of asthma during a 12-year period can be assessed. This gives us
a possibility to evaluate whether, e.g., the place or the performer, the
timing or frequency of control visits and actions performed at the control
visit can contribute to the outcome of asthma and how the care of chronic
asthma should be organised.
Statistical analysis
Statistical analysis involves the basic statistical tools for continuous,
categorical or dichotomous variables such as t-test, nonparametric tests
(e.g., Mann–Whitney) and analysis of variance. To evaluate the associations
between variables, χ2-test, correlation matrixes and regression analysis will
be used.22,23
Usually, the risk of asthma attacks is expressed as the total number of
events per patient or as yearly incidence of events.17 However, this analysis
does not take into account the timing of asthma attacks in relation to
changes in the other factors in asthma care (e.g., change in medication).
Even though Cox regression analysis can also involve time-dependent
variables, it will be inevitable to develop new ways to express the risk of
asthma attacks in relation to other changes in the condition of the patient.
Therefore, more sophisticated statistical methods will be included to
illustrate these connections. Cluster analyses of patients with asthma have
suggested that patients with asthma can be divided into different
phenotypes.24–26 However, the studies published thus far have been
cross-sectional and analysed their subjects at one single time point or after
only a short follow-up. Analysis of patient data with a long-term follow-up
time with time-dependent incidents will require a more sophisticated way
of performing cluster-type analysis. Thus, we will evaluate whether the
long-term follow-up will identify new and/or different clusters among
patients with adult-onset disease.
DISCUSSION
The characterisation of phenotypes of asthma is still in process.2,3
As the phenotypes have been characterised relatively recently
(i.e., between 2008 and 2014),24–26 there has not been enough
time for long-term follow-up studies to be conducted. Our recent
published systematic literature review27 identiﬁed only one
follow-up study5 of newly diagnosed adult-onset asthma lasting
⩾ 5 years. Another 2-year follow-up study of adult-onset asthma
has been recently published.6 Thus, the present study will increase
our knowledge on the long-term prognosis of new-onset asthma
diagnosed at adult age. The exclusion criteria in most studies with
asthma are current smoking or smoking history ⩾ 10 pack-years,
as well as the presence of co-morbidities. However, the
therapeutic response in patients with asthma who smoke remains
insufﬁcient.28,29 A recent survey9 indicated that over 60% of
asthma sufferers have one or more additional co-morbidities.
Furthermore, these co-morbidities associate with unscheduled
asthma care among adults.8,9 The patient population generally
included in clinical trials in asthma7 has been shown to represent
only 1.3–5.4% of those obstructive seen by a generalist.30 In the
present study, patients were not excluded because of smoking or
any signiﬁcant co-morbidity, suggesting that the study population
more closely represents that seen by a generalist.
Asthma is a common disease needing community solutions.14
Early diagnosis, active treatment and self-management are not
possible without the active role of primary-care professionals. The
key for the implementation of the Finnish Asthma Programme14,15
was the primary-care network of local asthma co-ordinators
(physicians and nurses) in local health-care centres.13 The Finnish
Asthma Programme reduced, e.g., the number of asthma hospital
days and morbidity.15,31 The published reports15,31 give indirect
evidence to support the primary-care-centred organisation of care
of chronic asthma, but more evidence is needed. The Finnish
Asthma Programme was extensively used in the Seinäjoki Hospital
district and has been evaluated.13,16,32–34 This allows us to
evaluate the diagnostic process, as well as the follow-up visits
made both in primary and specialised health care. According
to the principles of the Finnish Asthma Programme,13–15 a
hypothesis to be tested is that the diagnostic evaluations in
patients with adult-onset asthma can be performed in primary
care. Similarly, another hypothesis, supported also by the
literature,35 is that specialised nurse-centred follow-up visits are
important in the follow-up of most patients with adult-onset
asthma.
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